U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral ...

In an April 14 announcement, the FDA stated that Novo Nordisk — manufacturer of Ozempic and Wegovy — notified the agency that ...

Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new results ...

These drugs have transformed ... and the launch of Zepbound, a new obesity treatment, could erode Novo's market share in the years to come. Novo Nordisk’s dominance in the diabetes care market ...

Lilly markets its dual GIP and GLP-1 receptor agonist, tirzepatide, as Zepbound for obesity, while Novo Nordisk markets its semaglutide drug as Wegovy injection for weight management. Year to date ...

Novo Nordisk, the Danish pharmaceutical giant behind obesity drug, Wegovy, has engaged Slingshot to develop and manage its first consumer campaign in Australia. Novo Nordisk has previously focused ...

The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

Novo Nordisk will pay as much as $2 billion for a new obesity drug called UBT251 The company now holds the exclusive rights to develop, manufacture and sell the drug in much of the world It has ...

Novo Nordisk has won a Committee for Medicinal ... $1 billion or lower and pointing to lacklustre take-up of other new obesity drugs such as Eisai and Arena's Belviq (lorcaserin) and Vivus ...